Clinical trials: Epirubicin
Breast Cancer
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy
With the development of neoadjuvant therapy for tumors, neoadjuvant chemotherapy (NAC) has become one of the most common and effective methods for preoperative systemic treatment of locally advanced breast cancer (LABC).
- Trial name
- NCT04137640
- Testing
- palbociclib combined with letrozole, epirubicin combined with cyclophosphamide and sequential docetaxel
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Shengjing Hospital
Breast Cancer
Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
To evaluate safety and efficacy of vismodegib with standard neoadjuvant chemotherapy in breast cancer patients based on the CTCAE v4 2010 1.
- Trial name
- SHH-CM (NCT02694224)
- Testing
- vismodegib, Paclitaxel, Epirubicin
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Stage II Breast Cancer, Stage III Breast Cancer
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).
- Trial name
- NCT02115152
- Testing
- fluorouracil, capecitabine, cyclophosphamide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangxi Medical University
Breast Cancer
Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00309920
- Testing
- darbepoetin alfa, cyclophosphamide, docetaxel
- Where
- 47 sites in Germany
- Volunteers
- 1,234 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Triple Negative Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants…
- Trial name
- NCT03036488
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 193 sites in United States, Australia and 19 more
- Volunteers
- 1,174 people
- Sponsor
- Merck Sharp & Dohme LLC
Early Stage Breast Cancer
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Primarily, this clinical investigation compared overall survival and recurrence-free survival in patients with hormone receptor-negative breast cancer treated with pre- and postoperative chemotherapy vs.
- Trial name
- NCT00309569
- Testing
- Cyclophosphamide, Methotrexate, Fluorouracil
- Volunteers
- 429 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.
- Trial name
- EOXP (NCT00667420)
- Testing
- panitumumab, epirubicin, oxaliplatin, xeloda
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Breast Neoplasms
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
RATIONALE: Patients with HER2-negative breast cancer not responding to initial neoadjuvant chemotherapy might have lower chances for a pathologic complete response (pCR) at definitive surgery, indicating worse prognosis.
- Trial name
- NCT06121570
- Testing
- Sentinel Lymph Node Biopsy (SLNB), Doxorubicin, Epirubicin
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stage III Breast Cancer
A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer
The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for breast cancer patients.
- Trial name
- TENDENCY (NCT01907529)
- Testing
- docetaxel, epirubicin and cyclophosphamide, docetaxel, epirubicin and cyclophosphamide plus endostar
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Hebei Medical University Fourth Hospital
Triple Negative Breast Cancer
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).
- Trial name
- NCT05447702
- Testing
- Camrelizumab, Apatinib, Nab-paclitaxel
- Where
- China
- Volunteers
- 35 people
- Sponsor
- West China Hospital
HER2-Positive Breast Cancer
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer
This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant…
- Trial name
- NCT04094896
- Testing
- TCHP
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangdong Provincial People's Hospital
Soft Tissue Sarcoma, Bone Sarcoma
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial, with two stages. Stage one has two cohorts (soft tissue sarcoma and bone sarcoma) and stage two has eight cohorts (DDCS, EMC, VS, SFT…
- Trial name
- ImmunoSarc (NCT03277924)
- Testing
- Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin
- Where
- 13 sites in Italy, Spain and 1 more
- Volunteers
- 197 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Nodal T-follicular Helper Cell Lymphoma
Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
This is a prospective, multicenter, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of golidocitinib in combination with an anthracycline-based regimen as first-line treatment for patients with…
- Trial name
- NCT07753642
- Testing
- Golidocitinib, Doxorubicin, Epirubicin
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
TNBC, Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of Adjuvant treatment of TNBC breast cancer with Toripalimab combined…
- Trial name
- NCT06682195
- Testing
- Neoadjuvant chemotherapy combined with Toripalimab
- Where
- 13 sites in China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Breast Cancer
Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003577
- Testing
- CMF regimen, cyclophosphamide, epirubicin hydrochloride
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University Hospital Birmingham
Tubular Breast Cancer, Mucinous Breast Cancer
Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .
- Conditions
- Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast
- Trial name
- NCT03201861
- Testing
- Paclitaxel, Cisplatin, EC to docetaxel or paclitaxel
- Where
- China
- Volunteers
- 762 people
- Sponsor
- RenJi Hospital
Breast Cancer
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
The drugs FEC 100 (5-fluorouracil, epirubicin, and cyclophosphamide) are one of the approved options to treat Locally Advanced or Primary Metastatic Breast Cancer.
- Trial name
- VPA-FEC100 (NCT01010854)
- Testing
- VPA FEC100
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Multiple Myeloma, Primary Plasma Cell Leukemia
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma
- Conditions
- Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
- Trial name
- NCT06140966
- Testing
- Daratumumab, Carfilzomib, Lenalidomide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NSCLC (Non-small Cell Lung Cancer)
D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
This study is a single-arm prospective single-center phase II study. Subjects are untreated resectable stage II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC.
- Trial name
- NCT07016126
- Testing
- D-BACE in combination with chemotherapy and karelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer, Chemotherapy
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Breast cancer is the most common female malignancy in the world, and the leading cause of cancer-associated mortalities among women.
- Conditions
- Breast Cancer, Chemotherapy, Endocrine Breast Diseases
- Trial name
- NCT03373708
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Volunteers
- 200 people
- Sponsor
- Zhiyong Yu